As a key mediator in immune responses and inflammatory pathways, CXCL10 has been identified as an effective prognostic marker significantly associated with the success of DAA treatment and SVR.[35] The regulation of CXCL10, resulting from DAA treatment, may improve glycemic control through its effects on liver function and metabolic homeostasis.[36] Inhibition of inflammatory factors, including CXCL10 by DAAs, may influence the development of diabetes by reducing insulin resistance and metabolic disorders. This evidence concerns the gene CXCL10 and Insulin resistance.